UCB SA (OTCMKTS:UCBJY – Get Free Report) shares passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $88.80 and traded as high as $92.34. UCB shares last traded at $91.70, with a volume of 3,768 shares traded.
UCB Stock Up 0.3 %
The company’s 50 day moving average price is $88.80 and its 200-day moving average price is $76.66.
UCB Company Profile
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Read More
- Five stocks we like better than UCB
- How to Use High Beta Stocks to Maximize Your Investing Profits
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- What Do S&P 500 Stocks Tell Investors About the Market?
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
